TMZ data, page-2

Table 1. Effect of MGMT Promoter Methylation Status on Survival, According to Random Treatment Assignment.* Promoter Status and Outcome Radiotherapy (N=100) Temozolomide plus Radiotherapy (N=106) Methylated MGMT promoter No. of patients 46 46 Progression-free survival Median duration (mo) 5.9 (5.3–7.7) 10.3 (6.5–14.0) Rate at 6 mo (%) 47.8 (33.4–62.3) 68.9 (55.4–82.4) Hazard ratio for death 1.00 0.48 (0.31–0.75) Overall survival Median duration (mo) 15.3 (13.0–20.9) 21.7 (17.4–30.4) Rate at 2 yr (%) 22.7 (10.3–35.1) 46.0 (31.2–60.8) Hazard ratio for death 1.00 0.51 (0.31–0.84) Unmethylated MGMT promoter No. of patients 54 60 Progression-free survival Median duration (mo) 4.4 (3.1–6.0) 5.3 (5.0–7.6) Rate at 6 mo (%) 35.2 (22.5–47.9) 40.0 (27.6–52.4) Hazard ratio for death 1.00 0.62 (0.42–0.92) Overall survival Median duration (mo) 11.8 (9.7–14.1) 12.7 (11.6–14.4) Rate at 2 yr (%) <2† 13.8 (4.8–22.7) Hazard ratio for death 1.00 0.69 (0.47–1.02)

https://www.nejm.org/doi/pdf/10.1056/NEJMoa043331